ACRS Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

18 days ago - By: Zacks Investment Research - Mentions: CORT

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates

24 days ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

2 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

2 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

4 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Leadership Transition

a year ago - By: Benzinga - Mentions: PCH WY GCMG

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

3 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

4 months ago - By: Zacks Investment Research - Mentions: NTRB

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: HROW

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

4 months ago - By: Benzinga - Mentions: SPY LOGI MSFT RCKY ...

Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus

4 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

5 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

5 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

5 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

6 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

7 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

7 months ago - By: Zacks Investment Research - Mentions: PSTV

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

7 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

7 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

7 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

9 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

9 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

9 months ago - By: Aclaris Therapeutics, Inc.

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

10 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

11 months ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

a year ago - By: Yahoo Finance - Mentions: RJF WY PCH GCMG

Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls

a year ago - By: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

a year ago - By: Aclaris Therapeutics, Inc.

ACLARIS THERAPEUTICS INC (ACRS) Stock News

ACRS Latest News, Press Relases and Analysis

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Aclaris Therapeutics Announces Leadership Transition

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference